Synopsis: GlaxoSmithKline Pharmaceuticals, Asarfi Hospital, and Aurobindo Pharma are in focus after announcing their December quarter results, drawing investor attention to their latest earnings updates.
Three healthcare stocks are drawing attention after announcing their December quarter results, highlighting strong revenue growth and improving profitability. Investors are closely watching these updates to gauge sector momentum and company performance. Quarterly earnings provide insight into operational efficiency, demand trends, and future outlook, making these results important for market participants tracking opportunities in the healthcare space. Here are three Healthcare stocks that announced their December Quarterly Results
With a market capitalization of Rs. 43,876.16 crore, the shares of Glaxosmithkline Pharmaceuticals Limited reached a high of Rs. 2,675.40 per equity share, rising nearly 6.55 percent from its previous day’s close price of Rs. 2,511. Since then, the stock has retreated and is currently trading at Rs. 2,570.40 per equity share.
Q3 FY26 Result Walkthrough:
Coming into the quarterly results of Glaxosmithkline Pharmaceuticals Limited, the company’s consolidated revenue from operations increased by 9.67 percent YOY, from Rs. 949.42 crore in Q3 FY25 to Rs. 1041.26 crore in Q3 FY26, and grew by 6.26 percent QoQ from Rs. 979.94 crore in Q2 FY26.
In Q3 FY26, Glaxosmithkline Pharmaceuticals Limited’s consolidated net profit increased by 28.60 percent YOY, reaching Rs. 295.62 crore compared to Rs. 229.88 crore during the same period last year. As compared to Q2 FY26, the net profit has increased by 14.81 percent, from Rs. 257.49 crore.
Brokerage Viewpoints:
Motilal Oswal, a prominent brokerage firm, has recommended a “Neutral” call on Glaxosmithkline Pharmaceuticals Limited with a target price of Rs. 2,700 per share, indicating an upside potential of 7.53 percent from its previous day’s close price of Rs. 2,511.
Motilal Oswal maintains a Neutral view on GlaxoSmithKline Pharmaceuticals after the company posted in-line revenue and its highest-ever quarterly EBITDA margin, reflecting improving profitability. Oncology products continue to drive specialty growth, supported by RUBY-1 and the scale-up of Zejula and Jemperli. The brokerage has raised earnings estimates by 5% for FY26 and 2% each for FY27 and FY28, and expects an earnings CAGR of about 13% over FY26–28, but sees valuations as fairly priced at current levels.
GlaxoSmithKline Pharmaceuticals Limited is a research-driven healthcare company that develops, manufactures, and sells prescription medicines and vaccines in India. Its portfolio covers anti-infectives, respiratory care, oncology, dermatology, and general medicines.
Asarfi Hospital Limited
With a market capitalization of Rs. 367.77 crore, the shares of Asarfi Hospital Limited were currently trading at Rs. 193.90 per equity share, rising nearly 2.59 percent from its previous day’s close price of Rs. 189.
Q3 FY26 Result Walkthrough:
Coming into the quarterly results of Asarfi Hospital Limited, the company’s consolidated revenue from operations increased by 40.04 percent YOY, from Rs. 32.89 crore in Q3 FY25 to Rs. 46.06 crore in Q3 FY26, and grew by 2.70 percent QoQ from Rs. 44.85 crore in Q2 FY26.
In Q3 FY26, Asarfi Hospital Limited’s consolidated net profit increased by 101.47 percent YOY, reaching Rs. 5.48 crore compared to Rs. 2.72 crore during the same period last year. As compared to Q2 FY26, the net profit has increased by 27.44 percent, from Rs. 4.30 crore.
Asarfi Hospital Limited operates a multi-speciality healthcare facility that provides medical treatment, diagnostics, and emergency care services. The hospital offers patient care across departments such as general medicine, surgery, and specialized treatments.
Aurobindo Pharma Limited
With a market capitalization of Rs. 69,812.36 crore, the shares of Aurobindo Pharma Limited were currently trading at Rs. 1,202 per equity share, rising nearly 0.06 percent from its previous day’s close price of Rs. 1,201.25.
Q3 FY26 Result Walkthrough:
Coming into the quarterly results of Aurobindo Pharma Limited, the company’s consolidated revenue from operations increased by 9.01 percent YOY, from Rs. 7,893.15 crore in Q3 FY25 to Rs. 8,604.51 crore in Q3 FY26, and grew by 4.46 percent QoQ from Rs. 8,236.96 crore in Q2 FY26.
In Q3 FY26, Aurobindo Pharma Limited’s consolidated net profit increased by 7.60 percent YOY, reaching Rs. 909.80 crore compared to Rs. 845.57 crore during the same period last year. As compared to Q2 FY26, the net profit has increased by 7.27 percent, from Rs. 848.13 crore.
Brokerage Viewpoints:
Macquarie, a prominent brokerage firm, has recommended a “Underperform” call on Aurobindo Pharma Limited with a target price of Rs. 1,050 per share, indicating a downside potential of 12.65 percent from its current market price.
Similarly, Citi has also recommended a “Sell” call on Aurobindo Pharma Limited with a target price of Rs. 1,010 per share, indicating a downside potential of 15.97 percent from its current market price.
Company Overview:
Aurobindo Pharma Limited is a global pharmaceutical manufacturer producing generic medicines and active pharmaceutical ingredients. The company operates end-to-end manufacturing from raw materials to finished formulations. Its products span therapeutic areas like antibiotics, cardiovascular, neurosciences, and anti-retrovirals.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
